Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

• Jesse M. Tettero,
• Lok Lam Ngai,
• Costa Bachas,
• Dimitri A. Breems,
• Thomas Fischer,
• Bjorn T. Gjertsen,
• Patrycja Gradowska,
• Laimonas Griskevicius,
• Jeroen J.W.M. Janssen,
• Gunnar Juliusson,
• Johan Maertens,
• Markus G. Manz,
• Thomas Pabst,
• Jakob Passweg,
• Kimmo Porkka,
• Peter J.M. Valk,
• Bob Löwenberg,
• Gert J. Ossenkoppele,
• Jacqueline Cloos

Affiliations

Jesse M. Tettero

Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands

Lok Lam Ngai

Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands

Costa Bachas

Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands

Dimitri A. Breems

Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium

Thomas Fischer

Otto von Guericke University Hospital Magdeburg, Magdeburg, Germany

Bjorn T. Gjertsen

Haukeland University Hospital, Bergen, Norway

Patrycja Gradowska

Dutch-Belgian Hemato-Oncology Cooperative Group Data Center–Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Laimonas Griskevicius

Vilnius University Hospital Santaros Klinikos and Vilnius University, Vilnius, Lithuania

Jeroen J.W.M. Janssen

Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands

Gunnar Juliusson

Skanes University Hospital, Lund, Sweden

Johan Maertens

University Hospital Gasthuisberg, Leuven, Belgium

Markus G. Manz

University Hospital, Zurich, Switzerland; Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland

Thomas Pabst

Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland; Department of Medical Oncology, Inselspital; University Hospital, Bern, Switzerland

Jakob Passweg

Swiss Group for Clinical Cancer Research(SAKK), Bern, Switzerland; University Hospital, Basel, Switzerland

Kimmo Porkka

Helsinki University Hospital Cancer Center, Helsinki, Finland

Peter J.M. Valk

Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Bob Löwenberg

Erasmus University Medical Center (MC) and Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Gert J. Ossenkoppele

Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands

Jacqueline Cloos

Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands; Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands